Invivoscribe
Invivoscribe's LabPMM Nabs NY State Approval for MRD Assay
The company can now offer the FLT3 ITD MRD Assay in New York state to assess measurable residual disease to guide treatment for acute myeloid leukemia patients.
Invivoscribe Acute Myeloid Leukemia Assay Nabs Regulatory Compliance in UK, Switzerland
The test detects FLT3 mutations, which are associated with poor prognosis in acute myeloid leukemia patients.
Invivoscribe LeukoStrat CDx Gets CE Mark, EMA Approval
The PCR-based test is designed to help in the selection of acute myelogenous leukemia patients eligible for certain treatments.
Invivoscribe, Complete Genomics Partner to Develop, Commercialize Oncology Biomarker Tests
The companies will collaborate to develop biomarkers tests for minimal residual disease (MRDs) in research and clinical setting using the DNBSeq sequencer.
Invivoscribe Leukemia CDx Assay Nabs IVDR Approval
The PCR-based test detects internal tandem duplications and tyrosine kinase domain mutations D835 and I836 in the FLT3 gene in patients with acute myelogenous leukemia.
Nov 27, 2018